• Zachary A Bornholdt, Andrew S Herbert, Chad E Mire, Shihua He, Robert W Cross, Anna Z Wec, Dafna M Abelson, Joan B Geisbert, Rebekah M James, Md Niaz Rahim, Wenjun Zhu, Viktoriya Borisevich, Logan Banadyga, Bronwyn M Gunn, Krystle N Agans, Ariel S Wirchnianski, Eileen Goodwin, Kevin Tierney, William S Shestowsky, Ognian Bohorov, Natasha Bohorova, Jesus Velasco, Eric Ailor, Do Kim, Michael H Pauly, Kevin J Whaley, Galit Alter, Laura M Walker, Kartik Chandran, Larry Zeitlin, Xiangguo Qiu, Thomas W Geisbert, and John M Dye.
• Mapp Biopharmaceutical, Inc., San Diego, CA, USA.
• Cell Host Microbe. 2019 Jan 9; 25 (1): 49-58.e5.

AbstractRecent and ongoing outbreaks of Ebola virus disease (EVD) underscore the unpredictable nature of ebolavirus reemergence and the urgent need for antiviral treatments. Unfortunately, available experimental vaccines and immunotherapeutics are specific for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective against other ebolaviruses associated with EVD, including Sudan virus (SUDV) and Bundibugyo virus (BDBV). Here we show that MBP134AF, a pan-ebolavirus therapeutic comprising two broadly neutralizing human antibodies (bNAbs), affords unprecedented effectiveness and potency as a therapeutic countermeasure to antigenically diverse ebolaviruses. MBP134AF could fully protect ferrets against lethal EBOV, SUDV, and BDBV infection, and a single 25-mg/kg dose was sufficient to protect NHPs against all three viruses. The development of MBP134AF provides a successful model for the rapid discovery and translational advancement of immunotherapeutics targeting emerging infectious diseases.Copyright © 2018 Elsevier Inc. All rights reserved.

49 keywords...

hide…